What is august bioservices?
Founded in 2017 and headquartered in Nashville, Tennessee, August Bioservices comprises a team of seasoned life science professionals dedicated to delivering rigorous research, pharmaceutical development, and manufacturing solutions. The company serves clients across the pharmaceutical and biotechnology industries, emphasizing integrity, persistence, and ingenuity in overcoming challenges to achieve client objectives. This enterprise-level funding indicates a company poised for significant scaling and expansion within its specialized market.
How much funding has august bioservices raised?
august bioservices has raised a total of $88.6M across 2 funding rounds:
Series A
$23.6M
Series B
$65M
Series A (2021): $23.6M with participation from Oak HC/FT and Polaris Partners
Series B (2022): $65M led by Polaris Partners and Oak HC/FT
Key Investors in august bioservices
Polaris Partners
Polaris Partners is a venture capital firm that specializes in backing transformational companies in the biotech and healthcare sectors. With over two decades of experience, they partner with entrepreneurs to create successful business solutions, providing coaching, advice, and resources for growth.
Oak HC/FT
Founded in 2014, Oak HC/FT is the premier venture growth-equity fund investing in Healthcare Information & Services ("HC") and Financial Services Technology ("FT"). With $3.3 billion in assets under management, they are focused on driving transformation in these industries by providing entrepreneurs and companies with strategic counsel, board-level participation, business plan execution and access to our extensive network of industry leaders.
What's next for august bioservices?
The recent major strategic investment in August Bioservices signals a critical phase of growth and development. With substantial backing, the company is expected to accelerate its service offerings, potentially expanding its research capabilities, enhancing its pharmaceutical development pipeline, and increasing its manufacturing capacity. This capital infusion will likely fuel strategic initiatives aimed at solidifying its market position and driving innovation in the competitive life sciences landscape.
See full august bioservices company page
